SynAct Pharma

Executive Summary

SynAct Pharma is a Swedish clinical-stage biotechnology company developing novel oral small molecules and peptides that resolve inflammation by activating melanocortin receptors, restoring immune balance rather than suppressing it. The lead candidate, resomelagon (AP1189), is a once-daily oral therapy targeting chronic inflammatory/autoimmune diseases and hyperinflammatory stages of severe viral infections. Currently in Phase 1, the company aims to demonstrate safety and tolerability, with potential to address significant unmet needs in conditions like rheumatoid arthritis and acute respiratory distress syndrome. Its differentiated mechanism could lead to improved efficacy and safety profiles compared to current immunosuppressants.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 data readout for resomelagon (AP1189)65% success
• Q2 2027Initiation of Phase 2a trial in chronic inflammatory indication50% success
• TBDExpansion into hyperinflammatory viral indication with preclinical proof-of-concept40% success